Potential to use Deoxymabs to treat autoimmune diseases
0
Patrys has announced that new data from preclinical studies using PAT-DX1 in animal models of anti neutrophil cytoplasmic antibody (ANCA)…
Quarterly Activities Report and 4C | 31 December 2023
Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31…
GMP Production of PAT-DX1 Next Quarter
Patrys is pleased to announce that its Contract Manufacturing and Development Oganisation (CDMO) has confirmed that a manufacturing slot for…
Patrys Receives R&D Tax Incentive Refund
Patrys has today announced that its wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has received a $2.7 million refund for the…
Quarterly Activities Report and 4C Quarterly Cash Flow Report
Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30…
Data to be presented at leading brain cancer conference
Patrys is pleased to announce that data from preclinical studies using PAT-DX1 and PAT-DX3 in animal models of high grade…
Retirement of Non-Executive Director
Patrys has today announced the retirement of Ms Suzy Jones as a Director of Patrys effective from close of business…
Patrys FY23 Annual Report
Patrys has today released its Annual Report for the 2022-23 Financial Year (FY23). Highlights include: Successful completion of the PAT-DX1…
Quarterly Activities Report and 4C | 30 June 2023
Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30…
Patrys featured as one of Top 10 Best Healthcare Companies in Australia
Patrys has been featured as one of the Top 10 Best Healthcare Companies in Australia in Insights Care Magazine. CEO and MD,…